Keywords: Summit Pharma, Neuralstem, Antidepressant, NSI-189, Japan

Summit Pharma gets exclusive agency for Neuralstem’s NSI-189 in Japan

Article | 08 June 2011

Print This

USA-based stem cell development firm Neuralstem (NYSE Amex: CUR) has signed an exclusive agency licensing agreement with Japan’s ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in